✉news HealthMedicine first seen 7 d ago, last 6 d ago, peak #15
Biosimilars user fee program seen as boost for competition
Original: How the biosimilars user fee program supports competition and patients
PhRMA is highlighting how the biosimilars user fee program, under which the FDA collects fees from companies to help fund review of biosimilar products, supports competition and benefits patients. The industry group's framing suggests the program helps bring lower-cost alternatives to expensive biologic medicines to market, expanding treatment options and reducing costs in the US pharmaceutical market.
Why now: Ongoing policy debate over drug prices and increasing access to affordable biosimilar medicines
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3772247